Patents by Inventor Wanjung Tsai

Wanjung Tsai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230192679
    Abstract: Crystalline forms and pharmaceutical composition of a PRMT5 inhibitor of formula (I), methods of making PRMT5 inhibitor of formula (I) and crystalline forms thereof, methods of making the pharmaceutical compositions of the PRMT5 inhibitor of formula (I) and methods of using the PRMT5 inhibitor of formula (I) or crystalline solid forms and pharmaceutically acceptable compositions thereof.
    Type: Application
    Filed: December 16, 2022
    Publication date: June 22, 2023
    Inventors: Kevin M. Cottrell, Sapna Makhija Garad, Magnus Ronn, Kimberly Jane Briggs, Erik William Wilker, Matthew Robert Tonini, Minjie Zhang, Alice Wanjung Tsai-Marie, Jianglin Liang, Hongming Li
  • METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND DNA-PK INHIBITORS
    Publication number: 20220088043
    Abstract: Described herein are methods of treating a proliferative disease in a subject by administering a DNA-damaging agent and between about 8 and about 48 hours later administering to the subject a DNA-PK inhibitor. Exemplary DNA-PK inhibitors are represented by Formula (B-I): and by pharmaceutically acceptable salts thereof, wherein R1, Q, Ring A, and Ring B are as defined herein.
    Type: Application
    Filed: July 29, 2021
    Publication date: March 24, 2022
    Inventors: Diane Boucher, Shawn M. Hillier, Wanjung Tsai, Brian Hare, William Markland, David A. Newsome, Marina S. Penney
  • Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
    Patent number: 11110108
    Abstract: Described herein are methods of treating a proliferative disease in a subject by administering a DNA-damaging agent and between about 8 and about 48 hours later administering to the subject a DNA-PK inhibitor. Exemplary DNA-PK inhibitors are represented by Formula (B-I): and by pharmaceutically acceptable salts thereof, wherein R1, Q, Ring A, and Ring B are as defined herein.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: September 7, 2021
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Diane M. Boucher, Shawn M. Hillier, Wanjung Tsai, Brian Hare, William Markland, David A. Newsome, Marina S. Penney
  • METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND DNA-PK INHIBITORS
    Publication number: 20200016181
    Abstract: Described herein are methods of treating a proliferative disease in a subject by administering a DNA-damaging agent and between about 8 and about 48 hours later administering to the subject a DNA-PK inhibitor. Exemplary DNA-PK inhibitors are represented by Formula (B-I): and by pharmaceutically acceptable salts thereof, wherein R1, Q, Ring A, and Ring B are as defined herein.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 16, 2020
    Inventors: Diane M. Boucher, Shawn M. Hillier, Wanjung Tsai, Brian Hare, William Markland, David A. Newsome, Marina S. Penney
  • Inhibitors of influenza viruses replication
    Patent number: 9771361
    Abstract: Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: are Form A of HCl salt of Compound (1).½H2O, Form F of HCl salt of Compound (1).3H2O, Form D of HCl salt of Compound (1), Form A of Compound (1), and Form A of tosylate salt of Compound (1). Such polymorphic forms are employed for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: September 26, 2017
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kwame W. Nti-Addae, Michael Waldo, Simon Adam O'Neil, John Gregg Van Alsten, Dainius Macikenas, Praveen Mudunuri, Yi Shi, Mark Willem Ledeboer, Valdas Jurkauskas, Ales Medek, Steven Jones, Randal Byrn, Mohammed Asmal, Sarah Marie Robertson, Wanjung Tsai
  • INHIBITORS OF INFLUENZA VIRUSES REPLICATION
    Publication number: 20160251353
    Abstract: Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: are Form A of HCl salt of Compound (1).½H2O, Form F of HCl salt of Compound (1).3H2O, Form D of HCl salt of Compound (1), Form A of Compound (1), and Form A of tosylate salt of Compound (1). Such polymorphic forms are employed for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.
    Type: Application
    Filed: May 10, 2016
    Publication date: September 1, 2016
    Inventors: Kwame W. Nti-Addae, Michael Waldo, Simon Adam O'Neil, John Gregg Van Alsten, Dainius Macikenas, Praveen Mudunuri, Yi Shi, Mark Willem Ledeboer, Valdas Jurkauskas, Ales Medek, Steven Jones, Randal Byrn, Mohammed Asmal, Sarah Marie Robertson, Wanjung Tsai